文献速递胃肠动力与功能性疾病消化内镜

难治性胃轻瘫患者大队列胃经口内镜下肌切开术4年随访结局(附视频)

Gastric peroral endoscopic myotomy outcomes after 4 years of follow-up in a large cohort of patients with refractory gastroparesis (with video).
PubMed 文献 · Gastrointest Endosc · 2022-04-02

该研究纳入374例难治性胃轻瘫患者,评估胃经口内镜下肌切开术(G-POEM)后48个月的疗效与预测因素。48个月时102例完成随访,临床成功率为77.5%,糖尿病胃轻瘫结局最佳;糖尿病胃轻瘫、早期诊断、恶心呕吐、6个月时GCSI评分1.5-2及RP4H<10%为长期成功的预测因素。

要点

  • G-POEM后48个月临床成功率为77.5%,糖尿病胃轻瘫患者结局最佳。
  • 长期成功预测因素包括糖尿病胃轻瘫、早期诊断、恶心呕吐、6个月GCSI评分1.5-2及RP4H<10%。
  • 作者认为G-POEM是难治性胃轻瘫的有效4年治疗方法,尤其对糖尿病胃轻瘫,可能为一线治疗。

核心结论

  • G-POEM是难治性胃轻瘫患者有效的4年治疗方法,尤其在糖尿病胃轻瘫患者中,确立了其作为潜在一线治疗的地位。
  • 需要随机对照临床试验来证实这些结果。

研究设计与样本

  • 研究纳入确诊的难治性胃轻瘫患者,于2017年4月至2021年12月间进行评估。
  • 共纳入374例难治性胃轻瘫患者:糖尿病胃轻瘫141例(37.7%),特发性胃轻瘫115例(30.7%),术后胃轻瘫102例(27.3%),其他病因16例(4.3%)。
  • 在1、6、12、18、24、30、36、42和48个月时进行胃轻瘫主要症状指数(GCSI)评分、4小时保留百分比(RP4H)、平均半排空时间(MHET)和36项短期调查(SF-36)。
  • 48个月评估时,102例患者完成随访(糖尿病胃轻瘫58例,特发性胃轻瘫22例,术后胃轻瘫18例,其他4例)。

主要发现

  • G-POEM前GCSI评分为3.84±0.53,48个月评估时改善至2.1±0.70(P<.001)。
  • G-POEM前RP4H为44%(四分位距[IQR],11-68),48个月评估时改善至15.5%(IQR,0-36;P=.021)。
  • G-POEM前MHET为246分钟(IQR,150-368),48个月评估时改善至135分钟(IQR,67-290;P=.045)。
  • 48个月评估时临床成功率为77.5%。
  • 糖尿病胃轻瘫结局最佳(糖尿病胃轻瘫 vs 特发性胃轻瘫 vs 术后胃轻瘫 vs 其他:86.5% vs 72.5%[P=.001] vs 72.1%[P=.003] vs 68.8%[P<.001])。

关键数值与推荐

  • 长期成功预测因素:糖尿病胃轻瘫(比值比[OR],5.113;95%置信区间[CI],1.643-5.981;P=.035)。
  • 长期成功预测因素:早期诊断(OR,2.455;95%CI,1.129-3.522;P=.042)。
  • 长期成功预测因素:恶心/呕吐(OR,3.541;95%CI,1.881-5.511;P=.012)。
  • 长期成功预测因素:6个月时GCSI评分(1.5-2)(OR,3.612;95%CI,2.122-5.317;P=.022)。
  • 长期成功预测因素:6个月时RP4H<10%(OR,2.188;95%CI,1.435-4.233;P=.039)。

临床怎么用

  • 作者认为G-POEM是难治性胃轻瘫患者有效的4年治疗方法,尤其在糖尿病胃轻瘫患者中,可能为一线治疗。
  • 作者指出需要随机对照临床试验来证实这些结果。

局限性

  • 需要随机对照临床试验来证实这些结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Gastric peroral endoscopic myotomy (G-POEM) is used for refractory gastroparesis (RG) with good early-term but variable mid- and long-term outcomes. Limited data exist about candidates and long-term clinical and predictive factors. Our aim was to evaluate the 4-year follow-up efficacy and predictive factors in patients with RG. METHODS: Confirmed RG patients were included and evaluated between April 2017 and December 2021. Gastroparesis Cardinal Symptom Index (GCSI) score, retention percentage at 4 hours (RP4H), mean half-emptying time (MHET), and the 36-item short-form survey (SF-36) were performed at 1, 6, 12, 18, 24, 30, 36, 42, and 48 months. RESULTS: After G-POEM, 374 patients with RG were included: 141 patients (37.7%) had diabetic gastroparesis (DG), 115 (30.7%) had idiopathic gastroparesis (IG), 102 (27.3%) had postsurgical gastroparesis (PSG), and 16 (4.3%) had other etiologies. After the 48-month evaluation, 102 patients completed follow-up (DG, 58; IG, 22; PSG, 18; other, 4). Before G-POEM, GCSI score, RP4H, and MHET were 3.84 ± .53, 44% (interquartile range [IQR], 11-68), and 246 minutes (IQR, 150-368), respectively, and after the 48-month evaluation improved to 2.1 ± .70 (P < .001), 15.5% (IQR, 0-36; P = .021), and 135 minutes (IQR, 67-290; P = .045), respectively. At the 48-month evaluation, clinical success was 77.5%. DG showed the best outcomes (DG vs IG vs PSG vs other: 86.5% vs 72.5% [P = .001] vs 72.1% [P = .003] vs 68.8% [P < .001]). Long-term success predictors were DG (odds ratio [OR], 5.113; 95% confidence interval [CI], 1.643-5.981; P = .035), early diagnosis (OR, 2.455; 95% CI, 1.129-3.522; P = .042), nausea/vomiting (OR, 3.541; 95% CI, 1.881-5.511; P = .012), GCSI score at 6 months (1.5-2) (OR, 3.612; 95% CI, 2.122-5.317; P = .022), and RP4H <10% at 6 months (OR, 2.188; 95% CI, 1.435-4.233; P = .039). CONCLUSIONS: G-POEM is an effective 4-year treatment in patients with RG, especially in DG, establishing a potential first-line therapy in these patients. However, randomized controlled clinical trials are needed to confirm these results. (Clinical trial registration number: NTC03126513.).

来源:Gastrointest Endosc,查看原文。版权归原作者所有。

引用

  1. Hernández Mondragón OV, Contreras LFG, Velasco GB, et al. Gastric peroral endoscopic myotomy outcomes after 4 years of follow-up in a large cohort of patients with refractory gastroparesis (with video). Gastrointest Endosc. 2022. PMID: 35378136. doi:10.1016/j.gie.2022.03.025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。